2-deoxy-2[18F]fluoro-D-glucose positron emission tomography–computed tomography in rheumatological diseases. (31st August 2021)

• Record Type: Journal Article
• Authors: Subesinghe, Manil; Bhuva, Shaheel; Arumalla, Nikita; Cope, Andrew; D'Cruz, David; Subesinghe, Sujith
• Is Part Of: Rheumatology. Volume 61:Number 5(2022)
• Page Start: 1769
• Page End: 1782
• Publication Date: 2021-08-31
• Subjects: 18F-fluorodeoxyglucose -- PET-CT -- inflammation -- rheumatological diseases; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/keab675
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: 2-deoxy-2[ 18 F]fluoro-D-glucose (FDG) PET-CT has revolutionized oncological imaging. The cellular processes that make cancer cells visible on FDG PET-CT also occur in a number of inflammatory cells. Exploiting this phenomenon has led to a growth of evidence supporting the use of FDG PET-CT in a wide range of infective and inflammatory diseases. Rheumatological diseases can affect multiple sites within the musculoskeletal system alongside multi-organ extra-articular disease manifestations. Inflammation is central to these diseases, making FDG PET-CT a logical choice. In this review article we describe the various applications of FDG PET-CT in rheumatological diseases using illustrative examples to highlight the beneficial role of FDG PET-CT in each case.